atai Life Sciences N.V. announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai?s supervisory board subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer and Chairman of Marinus Pharmaceuticals Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operating Officer at Pacira Pharmaceuticals Inc. and portfolio manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group, earning his medical degree from the Albert Einstein College of Medicine and his undergraduate degree from Cornell University.

Laurent Fischer, M.D., is the CEO and President of Adverum Biotechnologies and serves on the Board of Directors at Mirum Pharmaceuticals Inc., Lycia Therapeutics and Teal. Previously, Dr. Fischer was Chairman of CTI Biopharma, CEO of Tobira Therapeutics (subsequently Allergan), and held leadership roles at Jennerex, RXCentric, MedVantx, Dupont Pharmaceuticals, Dupont-Merck, and F. Hoffmann-La Roche. Dr. Fischer earned an undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Further, the Company announced that after four years of service, Jason Camm has stepped down from the Board.